| Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome. | Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.
Lian B, Lu J, Fang X, Zhang Y, Wang W, He Y, Yu H, Li F, Wang J, Chen W, Qi X., Free PMC Article | 09/24/2024 |
| NMR-identification of the interaction between BRCA1 and the intrinsically disordered monomer of the Myc-associated factor X. | NMR-identification of the interaction between BRCA1 and the intrinsically disordered monomer of the Myc-associated factor X.
Epasto LM, Pötzl C, Peterlik H, Khalil M, Saint-Pierre C, Gasparutto D, Sicoli G, Kurzbach D., Free PMC Article | 02/20/2024 |
| A recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of c-Myc target genes. | A recurrent de novo MAX p.Arg60Gln variant causes a syndromic overgrowth disorder through differential expression of c-Myc target genes.
Harris EL, Roy V, Montagne M, Rose AMS, Livesey H, Reijnders MRF, Hobson E, Sansbury FH, Willemsen MH, Pfundt R, Warren D, Long V, Carr IM, Brunner HG, Sheridan EG, Firth HV, Lavigne P, Poulter JA., Free PMC Article | 01/29/2024 |
| Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma. | Validation of Myc-Associated Protein X (MAX) regulation in growth hormone secreting and nonfunctional pituitary adenoma.
Tucker DW, Pangal DJ, Du R, Gogia AS, Tafreshi A, Ruzevick J, Hurth KT, Triche T Jr, Micko A, Carpten JD, Shiroishi MS, Carmichael JD, Rhie SK, Zada G., Free PMC Article | 05/8/2023 |
| MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration. | MORC2 and MAX contributes to the expression of glycolytic enzymes, breast cancer cell proliferation and migration.
Guddeti RK, Pacharla H, Yellapu NK, Karyala P, Pakala SB. | 02/23/2023 |
| Integrated analysis of mRNA-seq and miRNA-seq reveals the potential roles of Egr1, Rxra and Max in kidney stone disease. | Integrated analysis of mRNA-seq and miRNA-seq reveals the potential roles of Egr1, Rxra and Max in kidney stone disease.
Huang L, Shi Y, Hu J, Ding J, Guo Z, Yu B. | 12/31/2022 |
| Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours. | Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours.
Loughrey PB, Roncaroli F, Healy E, Weir P, Basetti M, Casey RT, Hunter SJ, Korbonits M., Free PMC Article | 09/24/2022 |
| miR-22 Suppresses EMT by Mediating Metabolic Reprogramming in Colorectal Cancer through Targeting MYC-Associated Factor X. | miR-22 Suppresses EMT by Mediating Metabolic Reprogramming in Colorectal Cancer through Targeting MYC-Associated Factor X.
Xia S, Wang X, Wu Y, Zhou T, Tian H, Liu Z, Li L, Yan Z, Zhang G., Free PMC Article | 09/10/2022 |
| MAX deficiency impairs human endometrial decidualization through down-regulating OSR2 in women with recurrent spontaneous abortion. | MAX deficiency impairs human endometrial decidualization through down-regulating OSR2 in women with recurrent spontaneous abortion.
Ma W, Cao M, Bi S, Du L, Chen J, Wang H, Jiang Y, Wu Y, Liao Y, Kong S, Liu J., Free PMC Article | 05/7/2022 |
| Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With Hereditary Pheochromocytoma Associated With a MAX Deleterious Variant. | Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With Hereditary Pheochromocytoma Associated With a MAX Deleterious Variant.
Duarte DB, Ferreira L, Santos AP, Costa C, Lima J, Santos C, Afonso M, Teixeira MR, Carvalho R, Cardoso MH., Free PMC Article | 12/25/2021 |
| Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? | Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?
Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T, Hockings JI, Hockings NG, Kirk J, Leo PJ, Love AJ, Luxford C, Marshall M, Mete O, Pennisi DJ, Brown MA, Gill AJ, Hockings GI, Clifton-Bligh RJ, Duncan EL. | 10/23/2021 |
| Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion. | Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion.
Petignot S, Daly AF, Castermans E, Korpershoek E, Scagnol I, Beckers P, Dideberg V, Rohmer V, Bours V, Beckers A. | 08/21/2021 |
| Clinical description & molecular modeling of novel MAX pathogenic variant causing pheochromocytoma in family, supports paternal parent-of-origin effect. | Clinical description & molecular modeling of novel MAX pathogenic variant causing pheochromocytoma in family, supports paternal parent-of-origin effect.
Richter JE Jr, Hines S, Selvam P, Atwal H, Farres H, Caulfield TR, Atwal PS. | 07/24/2021 |
| Inchworm stepping of Myc-Max heterodimer protein diffusion along DNA. | Inchworm stepping of Myc-Max heterodimer protein diffusion along DNA.
Dai L, Yu J. | 03/20/2021 |
| MYC-Associated Factor MAX is a Regulator of the Circadian Clock. | MYC-Associated Factor MAX is a Regulator of the Circadian Clock.
Blaževitš O, Bolshette N, Vecchio D, Guijarro A, Croci O, Campaner S, Grimaldi B., Free PMC Article | 12/19/2020 |
| Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma. | Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Yamashita T, Higashi M, Momose S, Adachi A, Watanabe T, Tanaka Y, Tokuhira M, Kizaki M, Tamaru JI., Free PMC Article | 12/5/2020 |
| The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells. | The MNT transcription factor autoregulates its expression and supports proliferation in MYC-associated factor X (MAX)-deficient cells.
Lafita-Navarro MC, Liaño-Pons J, Quintanilla A, Varela I, Blanco R, Ourique F, Bretones G, Aresti J, Molina E, Carroll P, Hurlin P, Romero OA, Sanchez-Céspedes M, Eisenman RN, Delgado MD, León J., Free PMC Article | 10/24/2020 |
| lncEGFL7OS is required for MAPK and AKT pathway activation by regulating EGFL7/miR-126 expression. | LncEGFL7OS regulates human angiogenesis by interacting with MAX at the EGFL7/miR-126 locus.
Zhou Q, Yu B, Anderson C, Huang ZP, Hanus J, Zhang W, Han Y, Bhattacharjee PS, Srinivasan S, Zhang K, Wang DZ, Wang S., Free PMC Article | 04/11/2020 |
| Select E-box locations that can be bound by both MITF and MYC-MAX form a separate class of MITF binding sites characterized by differential sequence content in the flanking region, diminished interaction with SOX10, higher evolutionary conservation, and less tissue-specific chromatin organization. | Local genomic features predict the distinct and overlapping binding patterns of the bHLH-Zip family oncoproteins MITF and MYC-MAX.
Hejna M, Moon WM, Cheng J, Kawakami A, Fisher DE, Song JS., Free PMC Article | 02/8/2020 |
| the MYC associated transcription factor X (MAX) undergoes nanoscale conformational fluctuations in the DNA-bound state, which is consistent with facilitated dissociation from or diffusion along DNA strands by transiently reducing binding energies | Conformational tuning of a DNA-bound transcription factor.
Sicoli G, Vezin H, Ledolter K, Kress T, Kurzbach D., Free PMC Article | 12/7/2019 |
| High MAX expression is associated with lung cancer. | A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer.
Liu L, Song X, Li X, Xue L, Ding S, Niu L, Xie L, Song X. | 11/30/2019 |
| MAX loss leads to a significant reduction in MYC protein levels and down-regulation of direct transcriptional targets, including regulators of MYC stability | Max deletion destabilizes MYC protein and abrogates Eµ-Myc lymphomagenesis.
Mathsyaraja H, Freie B, Cheng PF, Babaeva E, Catchpole JT, Janssens D, Henikoff S, Eisenman RN., Free PMC Article | 11/2/2019 |
| Importance of MAX mutations in Endometrial cancer, pointing to increased vascularity as one mechanism contributing to clinical aggressiveness of endometrial cancer. | MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.
Walker CJ, Rush CM, Dama P, O'Hern MJ, Cosgrove CM, Gillespie JL, Zingarelli RA, Smith B, Stein ME, Mutch DG, Shakya R, Chang CW, Selvendiran K, Song JW, Cohn DE, Goodfellow PJ., Free PMC Article | 08/3/2019 |
| RASSF7 competed with MAX in the formation of a heterodimeric complex with c-Myc and attenuated its occupancy on target gene promoters to regulate transcription. | The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A, Mamidi A, Desai P, Sivagnanam A, Perumalsamy LR, Ramakrishnan C, Gromiha M, Rajalingam K, Mahalingam S., Free PMC Article | 03/9/2019 |
| Using isothermal calorimetry, the study found that Myc phosphorylation destabilizes this ternary protein-DNA complex by decreasing Myc's affinity for Max by 2 orders of magnitude, suggesting a major effect of phosphorylation on this complex. | Myc phosphorylation in its basic helix-loop-helix region destabilizes transient α-helical structures, disrupting Max and DNA binding.
Macek P, Cliff MJ, Embrey KJ, Holdgate GA, Nissink JWM, Panova S, Waltho JP, Davies RA., Free PMC Article | 01/26/2019 |